The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients
- PMID: 20651383
The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients
Abstract
Background: The therapeutic role of pelvic lymph-node dissection (PLND) for prostate cancer (PCa) is still unclear. The aim of this study was to assess the impact of the number of lymph nodes (LN) retrieved at PLND during radical prostatectomy (RP) on biochemical relapse (BCR) in node-negative patients.
Patients and methods: From October 1995 to June 2009, 1510 consecutive PCa patients underwent RP at the University of Bologna hospital. A retrospective analysis was performed on 614 pT2-4N0 patients with a minimum follow-up of 12 months. All 614 patients underwent limited or extended PLND during RP. BCR-free survival was estimated using the Kaplan-Meier method. Cox regression was applied to analyse survivals rates. Patients were divided into two groups: group 1 (n=295) had 1 to 9 retrieved LNs and group 2 (n=319) had 10 or more retrieved. The parameters analysed were age, PSA, clinical and pathological Gleason score (GS), stage, margin status and adjuvant radiotherapy (ART). BCR was defined as PSA greater than 0.2 ng/ml.
Results: Mean follow-up time was 62.5+/-39.7 months. Group 2 showed a significantly lower BCR than group 1 (p=0.019). LN group, PSA, clinical and pathological GS, pathological stage and ART all showed an independent and significant relationship with BCR using multivariate analysis.
Conclusion: In node-negative patients, a more extensive PLND affects BCR-free survival positively. A more extensive PLND may have a therapeutic role by removal of micrometastases.
Similar articles
-
The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.BJU Int. 2011 Oct;108(8):1262-8. doi: 10.1111/j.1464-410X.2010.10016.x. Epub 2011 Mar 29. BJU Int. 2011. PMID: 21446934
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
-
Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.Urology. 2008 Jan;71(1):141-5. doi: 10.1016/j.urology.2007.08.027. Urology. 2008. PMID: 18242383
-
Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4. BJU Int. 2013. PMID: 22487441
-
Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.Eur Urol. 2007 Jul;52(1):29-37. doi: 10.1016/j.eururo.2007.04.020. Epub 2007 Apr 11. Eur Urol. 2007. PMID: 17448592 Review.
Cited by
-
Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.J Clin Med. 2021 Mar 2;10(5):999. doi: 10.3390/jcm10050999. J Clin Med. 2021. PMID: 33801231 Free PMC article.
-
Effectiveness of extended pelvic lymphadenectomy in the survival of prostate cancer: a systematic review and meta-analysis.Cent European J Urol. 2018;71(3):262-269. doi: 10.5173/ceju.2018.1703. Epub 2018 Aug 20. Cent European J Urol. 2018. PMID: 30386645 Free PMC article. Review.
-
A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma.J Cancer Res Clin Oncol. 2014 Feb;140(2):243-56. doi: 10.1007/s00432-013-1574-2. Epub 2013 Dec 27. J Cancer Res Clin Oncol. 2014. PMID: 24369378 Free PMC article.
-
Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial.JMIR Res Protoc. 2018 Dec 13;7(12):e11256. doi: 10.2196/11256. JMIR Res Protoc. 2018. PMID: 30545809 Free PMC article.
-
Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the Aortic Bifurcation in Higher Risk Prostate Cancer: Early Toxicity Outcomes.Biomed Res Int. 2015;2015:696439. doi: 10.1155/2015/696439. Epub 2015 Oct 11. Biomed Res Int. 2015. PMID: 26539522 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous